Decisions of young women with breast cancer regarding fertility preservation before cancer treatment and family building after treatment
Journal of Cancer Survivorship · 2026-08 · 20 (S1) · 209-216
DOI: 10.1007/s11764-025-01809-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Survivorship, online erschienen am 23.04.2025. Verfasst von Nadia Abdo und 8 weiteren Autor:innen. Beteiligte Einrichtung: UCSF - East Bay, Oakland, CA, USA. Hauptthemen laut MEDLINE: Fertility Preservation, Breast Neoplasms, Decision Making, Cancer Survivors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Approximately 19% of breast cancer cases in 2020 were diagnosed in women under age 50. These premenopausal women with early-stage breast cancer face unique challenges related to family building. This study examines the decision-making and outcomes of patients who pursue fertility preservation before treatment and family building afterwards. METHODS: Breast cancer survivors seen by a fertility nurse specialist before initiating cancer treatment at Memorial Sloan Kettering Cancer Center (MSKCC) between 2009 and 2017 were contacted to participate. Participants completed a web-based cross-sectional survey examining decisions made about fertility preservation, factors influencing them, and post-treatment reflections and outcomes. RESULTS: Prior to treatment, 168 women met with a reproductive endocrinologist and 116 underwent fertility preservation. After completing cancer treatment, 36 women had children and 15 of these women used eggs/embryos frozen prior to treatment. The majority of women deemed these factors "very important" when deciding whether to freeze eggs/embryos: a desire to have a biologic child, the ability to feel hopeful about their future, the chance of success, feeling overwhelmed by their diagnosis, and concerns about having regret if they didn't freeze their eggs/embryo. CONCLUSIONS: Over half of patients who attempted family building after treatment were able to have children. Many of these women used eggs/embryos frozen before treatment either by getting pregnant themselves or via surrogacy. IMPLICATIONS FOR CANCER SURVIVORS: This data stresses the importance of referring cancer patients early to a reproductive endocrinologist before initiation of systemic therapy and has high translational promise in the clinical care of all young female cancer survivors interested in fertility preservation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UCSF - East Bay, Oakland, CA, USA.
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
- Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Massachusetts General Hospital, Boston, MA, USA.
- Stanford University School of Medicine, Stanford, CA, USA.
- Perlmutter Cancer Center, New York, NY, USA.
Zitieren
APA
Abdo, N., Thom, B., Chang, C., Feldman, M., Benedict, C., Semler, R., Kelvin, J., Gemignani, M., & Goldfarb, S. (2026). Decisions of young women with breast cancer regarding fertility preservation before cancer treatment and family building after treatment. Journal of Cancer Survivorship, 20(S1), 209-216. https://doi.org/10.1007/s11764-025-01809-1
Vancouver
Abdo N, Thom B, Chang C, Feldman M, Benedict C, Semler R, et al. Decisions of young women with breast cancer regarding fertility preservation before cancer treatment and family building after treatment. Journal of Cancer Survivorship. 2026;20(S1):209-216. doi:10.1007/s11764-025-01809-1
BibTeX
@article{Abdo2026,
author = {Abdo, Nadia and Thom, Bridgette and Chang, Cassandra and Feldman, Maya and Benedict, Catherine and Semler, Rosemary and Kelvin, Joanne and Gemignani, Mary and Goldfarb, Shari},
title = {Decisions of young women with breast cancer regarding fertility preservation before cancer treatment and family building after treatment},
journal = {Journal of Cancer Survivorship},
year = {2026},
volume = {20},
number = {S1},
pages = {209--216},
doi = {10.1007/s11764-025-01809-1}
}
EUVIMED